Washington Trust CO Bei Gene, Ltd. Transaction History
Washington Trust CO
- $2.7 Billion
- Q1 2024
A detailed history of Washington Trust CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Washington Trust CO holds 16 shares of BGNE stock, worth $2,302. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16
Previous 10
60.0%
Holding current value
$2,302
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BGNE
# of Institutions
216Shares Held
45.1MCall Options Held
76.5KPut Options Held
72.3K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.52 Billion20.93% of portfolio
-
Capital International Investors Los Angeles, CA7.06MShares$1.02 Billion0.23% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$745 Million17.98% of portfolio
-
Primecap Management CO Pasadena, CA5MShares$720 Million0.59% of portfolio
-
Baillie Gifford & CO3.73MShares$537 Million0.46% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $14.9B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...